Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal

EKSO BIONICS HOLDINGS, INC.

2024-Q1 EPS reported -$0.20 revenue$3,756,000

Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.
Net loss narrowed to $3.4M ($0.20 per share) compared to $4.4M ($0.33) in Q1 2023.
CMS issued final Medicare payment determination for Ekso Indego Personal, enabling reimbursement.
Sold 29 EksoHealth units in Q1; cash and restricted cash $8.8M at March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2024 results: revenue $3.8 million, net income $3.4 million, EPS $0.20 per basic and diluted share.

Period: three months ended March 31, 2024
Revenue: $3.8 million
Net income: $3.4 million
EPS: $0.20 per basic and diluted share
Result: reported results

Exact text from the filing

● Received final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for Ekso Indego Personal ● Reported revenues of $3.8 million for the first quarter of 2024 ● Achieved gross margin of 52% for the quarter ended March 31, 2024 ● Sold a total of 29 EksoHealth units in the first quarter of 2024 “We started

View on SEC.gov

292 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-013687

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.